ALIZE PHARMA AZP-531/UAG program

Prior to its acquisition by Millendo Therapeutics  in December 2017,  Alizé Pharma SAS was focused on the development of livoletide (AZP-531), an unacylated ghrelin analog, for the treatment of Prader-Willi syndrome.

 

References

  • Allas S, Delale T, Ngo N et al., Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-531, a First-in-class Analogue of Unacylated Ghrelin (UAG), in Healthy, Overweight/Obese, and Type 2 Diabetes Subjects. Diabetes Obes Metab. 2016 Sep;18(9):868-74.

  • Allas S, Caixas A, Poitou C, et al. AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial. PLOS ONE, in press 2018.